Orphan drugs

Neurons
#AAV #BlackfinBio #FDA #Gene therapy #Neurology #Orphan drugs #Paediatrics #Rare disease

FDA clears gene therapy trial for rare neurological disease

The US Food and Drug Administration (FDA) has cleared BlackfinBio’s Investigational New Drug (IND) application for a Phase I/II clinical trial of novel adeno-associated virus (AAV) gene therapy, BFB-101, in children with Hereditary Spastic Paraplegia Type 47 (SPG47).  The trial will be conducted in the US at… Read More

#News #Regulatory

Monoclonal antibody
#Dermatology #FDA #Monoclonal antibodies #Orphan drugs #Rare disease

Dupixent for bullous pemphigoid under FDA priority review

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).  The sBLA is supported by data from a pivotal study evaluating the efficacy and safety of Dupixent in… Read More

#News #Regulatory

Small cell lung cancer
#Ariceum Therapeutics #FDA #Lung cancer #Oncology #Orphan drugs #Radiopharmaceuticals

Radiopharmaceutical cancer therapy granted orphan drug status

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Ariceum Therapeutics’ 225Ac-SSO110 (satoreotide) for the treatment of patients with small cell lung cancer (SCLC).  Ariceum has announced plans to commence Phase I/II human clinical development of 225Ac-satoreotide under the trial name, SANTANA-225… Read More

#News #Regulatory

FDA
#Antibiotic resistance #Antibiotics #FDA #MicuRx Pharmaceutical #Orphan drugs

Novel benzoxazole antibiotic gets FDA Orphan Drug Designation

MicuRx Pharmaceutical’s anti-infection drug MRX-5 has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) for the treatment of non-tuberculous mycobacteria (NTM) infections.  MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria… Read More

#News #Regulatory

Laboratory research
#Clinical trials #FDA #Funding #Orphan drugs #Rare disease

FDA awards grants to seven clinical trials for orphan products

The US Food and Drug Administration (FDA) has announced seven new clinical trial grants awarded under the Orphan Products Grants Program for clinical trials to address the unmet needs of people affected by rare diseases. In total, clinical researchers will receive approximately $17.2 million over the… Read More

#News #Regulatory

Monoclonal antibody
#Dermatology #Monoclonal antibodies #Orphan drugs #Sanofi

Biologic achieves improvements in bullous pemphigoid

A Dupixent (dupilumab) pivotal study (ADEPT) in bullous pemphigoid (BP) has met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate-to-severe disease. In the study, five times more Dupixent patients achieved sustained disease remission compared to those on placebo. Read More

#News

Human liver
#European Medicines Agency #Liver disease #Orphan drugs #Rare disease #SeaBeLife

Orphan drug prevents cell death in acute liver failure

Biotechnology company SeaBeLife has secured orphan drug designation (ODD) from the European Medicines Agency (EMA) for its drug candidate SBL01 in the treatment of acute liver failure (ALF). ALF occurs when the liver suddenly loses its ability to function in a person without a pre-existing liver… Read More

#News

#Cereno Scientific #European Commission #Hypertension #Orphan drugs #Rare disease

EU orphan designation for pulmonary hypertension drug

The European Commission has granted orphan medicinal product designation (OMPD) to Cereno Scientific’s lead drug candidate CS1 for pulmonary arterial hypertension (PAH). CS1 is an HDAC inhibitor that works through epigenetic modulation, being developed to offer improved quality of life and prolonged life for patients with… Read More

#News #Regulatory

FDA headquarters
#Bispecific Antibodies #FDA #Oncology #Orphan drugs #Phanes Therapeutics

Neuroendocrine carcinoma drug granted orphan status

Phanes Therapeutics’ PT217 has received orphan drug designation (ODD) for neuroendocrine carcinoma (NEC) from the US Food and Drug Administration (FDA). PT217 is a first-in-class bispecific antibody targeting delta-like ligand 3 (DLL3) and cluster of differentiation 47 (CD47) being developed for patients with NEC. Read More

#Cancer Research #News #Regulatory

Cancer tumour
#4SC #Lymphoma #Oncology #Orphan drugs #Switzerland

Swiss Orphan Drug Status for cutaneous T-cell lymphoma drug

The Swiss Agency for Therapeutic Products (SwissMedic) has granted Orphan Drug Status (ODS) to 4SC’s Kinselby (resminostat) for the treatment of cutaneous T-cell lymphoma (CTCL). In Switzerland, ODS provides privileged status to drugs that show promise for the treatment of rare diseases and qualifies 4SC for… Read More

#News #Regulatory

Premature baby in hospital
#EXO Biologics #Exosomes #Orphan drugs #Paediatrics #Phase I trial

EXO Biologics doses first cohort in MSC-based exosome clinical trial

EXO Biologics has completed dosing of the first cohort of patients in its EVENEW study, the first European Medicines Agency (EMA) authorised clinical trial involving mesenchymal stromal cell (MSC)-based exosomes. The Phase I/II clinical trial is testing the company’s lead candidate EXOB-001, developed to prevent bronchopulmonary… Read More

#News

MRI showing glioblastoma
#Brain cancer #European Medicines Agency #FDA #Oncology #Orphan drugs

Regulatory update for malignant glioma drug

Carthera, a spin-off from Sorbonne University, has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the use of carboplatin in the treatment of malignant glioma. Carthera is using carboplatin in the first registrational… Read More

#News #Regulatory

#Aardvark Therapeutics #Financing #Investment #Obesity #Orphan drugs #Rare disease

Funding of $85 million secured for Prader-Willi Syndrome drug

Aardvark Therapeutics has announced an $85 million oversubscribed Series C financing. The funding will be used to complete the clinical trials required for regulatory approval of Aardvark’s lead asset, ARD-101, for the treatment of hyperphagia in patients with Prader-Willi Syndrome (PWS), as well as to demonstrate… Read More

#Business & Investment #News

FDA
#Astellas Pharma #FDA #Orphan drugs #Paediatrics

FDA grants orphan and paediatric exclusivities for Cresemba

The US Food and Drug Administration (FDA) has granted orphan drug and paediatric exclusivity to Cresemba (isavuconazonium sulfate) for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in paediatric patients. In December 2023, Cresemba for injection was approved for paediatric patients one year of… Read More

#News #Regulatory

Pancreatic cancer
#FDA #Fibrosis #iOnctura #Oncology #Orphan drugs #Pancreatic cancer

Orphan Drug Designation for first-in-class autotaxin cancer therapy

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to iOnctura for its autotaxin inhibitor cambritaxestat for the treatment of pancreatic cancer. After assessing its novel chemical and biological properties, including an attractive non-clinical safety and efficacy profile, the FDA has granted… Read More

#Cancer Research #News #Regulatory